what happens after jump to $5 usa nasdaq, page-4

Now that we've bagged a couple of elephant deals I'm not so fussed about shareprices.

I'm more focused on the story. Pound for pound I reckon UNS is becoming the best value proposition out of all upcoming biotech/life science companies on the ASX.

* less risk than plain vanilla biotechs
* longer patent lives than most plain vanilla biotechs
* diversified products
* not far off from hugely significant revenue (2-3 years)
* tie ups with Pharma behemoths
* still a modest market cap